Literature DB >> 10414063

Reducing medical attrition: the role of the Accession Medical Standards Analysis and Research Activity.

K L Clark1, R A Mahmoud, M R Krauss, P W Kelley, L K Grubb, M R Ostroski.   

Abstract

This paper illustrates how adding an epidemiologic perspective to medical accession policy development allows the Department of Defense to address unacceptably high rates of premature attrition, lost duty time, avoidable medical care costs, sick leave, disability, and various wasteful, inefficient practices. The Accession Medical Standards Analysis and Research Activity is a major new epidemiologic entity. Historically, military medical accession policy and waiver deliberations were based heavily on expert opinion. A common limitation of expert opinion is that although experience teaches much about individuals with certain conditions who develop problems, it does not teach about individuals with the same conditions who remain well. The Accession Medical Standards Analysis and Research Activity produces the analyses of epidemiologic data necessary for the joint personnel and medical flag-level Department of Defense Accessions Medical Standards Steering Committee to make evidence-based accession policy decisions.

Entities:  

Mesh:

Year:  1999        PMID: 10414063

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

Review 1.  Temporal changes in the physical fitness of US Army recruits.

Authors:  Joseph J Knapik; Marilyn A Sharp; Salima Darakjy; Sarah B Jones; Keith G Hauret; Bruce H Jones
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

2.  Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study.

Authors:  Vincent C Marconi; Greg A Grandits; Amy C Weintrob; Helen Chun; Michael L Landrum; Anuradha Ganesan; Jason F Okulicz; Nancy Crum-Cianflone; Robert J O'Connell; Alan Lifson; Glenn W Wortmann; Brian K Agan
Journal:  AIDS Res Ther       Date:  2010-05-27       Impact factor: 2.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.